NASDAQ:DRNA

Dicerna Pharmaceuticals Stock Forecast, Price & News

$25.56

+0.92 (+3.73 %)

(As of 01/25/2021 11:51 AM ET)

Add

Compare

Today's Range

$24.90

Now: $25.56▼

$25.56

50-Day Range

$21.49

MA: $23.27▼

$25.06

52-Week Range

$11.75

Now: $25.56▼

$27.10

Volume14,076 shs

Average Volume728,307 shs

Market Capitalization$1.92 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.33

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

MarketRank^™

Overall MarketRank^™

1.76 out of 5 stars

Medical Sector

158th out of 1,923 stocks

Pharmaceutical Preparations Industry

80th out of 773 stocks

3.5 Analyst's Opinion

Consensus Rating
Dicerna Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.33, Dicerna Pharmaceuticals has a forecasted upside of 35.0% from its current price of $25.44.
Amount of Analyst Coverage
Dicerna Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Dicerna Pharmaceuticals has received 434 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Dicerna Pharmaceuticals has received 291 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Dicerna Pharmaceuticals has received 59.86% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote “Outperform” if you believe DRNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Dicerna Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Dicerna Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dicerna Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,893,029.00 in company stock.
Percentage Held by Insiders
Only 11.30% of the stock of Dicerna Pharmaceuticals is held by insiders.
Percentage Held by Institutions
80.64% of the stock of Dicerna Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Dicerna Pharmaceuticals are expected to grow in the coming year, from ($1.02) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dicerna Pharmaceuticals is -15.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dicerna Pharmaceuticals is -15.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Dicerna Pharmaceuticals has a P/B Ratio of 11.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:DRNA

Previous Symbol

CUSIPN/A

CIK1399529

Webwww.dicerna.com

Phone617-621-8097

Employees187

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio2.62

Quick Ratio2.62

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$23.90 million

Price / Sales80.26

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.22 per share

Price / Book11.51

Profitability

EPS (Most Recent Fiscal Year)($1.76)

Net Income$-120,460,000.00

Net Margins-88.81%

Return on Equity-71.72%

Return on Assets-16.60%

Miscellaneous

Outstanding Shares75,045,000

Market Cap$1.92 billion

Next Earnings Date2/25/2021 (Estimated)

OptionableOptionable

$25.56

+0.92 (+3.73 %)

(As of 01/25/2021 11:51 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

How has Dicerna Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 50.1% and is now trading at $25.34.
View which stocks have been most impacted by COVID-19.

Is Dicerna Pharmaceuticals a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Dicerna Pharmaceuticals stock.
View analyst ratings for Dicerna Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dicerna Pharmaceuticals?

Wall Street analysts have given Dicerna Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dicerna Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Dicerna Pharmaceuticals.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.12. The biopharmaceutical company earned $48.88 million during the quarter, compared to the consensus estimate of $55.72 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 71.72% and a negative net margin of 88.81%.
View Dicerna Pharmaceuticals' earnings history.

What price target have analysts set for DRNA?

9 Wall Street analysts have issued 1 year target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $45.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $34.33 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Dicerna Pharmaceuticals' key competitors?

Some companies that are related to Dicerna Pharmaceuticals include Galapagos (GLPG), Allakos (ALLK), Schrödinger (SDGR), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), Perrigo (PRGO), Emergent BioSolutions (EBS), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), Eidos Therapeutics (EIDX), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE) and Hutchison China MediTech (HCM).
View all of DRNA's competitors.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:

Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 51, Pay $937.43k)
Dr. Bob D. Brown, Exec. VP of R&D and Chief Scientific Officer (Age 55, Pay $671.96k)
Dr. Ralf H. Rosskamp, Consultant (Age 67, Pay $707.13k)
Mr. Robert D. Ciappenelli M.B.A., Chief Commercial Officer (Age 53, Pay $339.51k)
Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 73)
Mr. Douglas W. Pagan, Chief Financial Officer (Age 48)
Mr. James B. Weissman, Exec. VP & COO (Age 58)
Ms. Ling Zeng J.D., Chief Legal Officer & Sec.
Ms. Regina DeTore Paglia, Chief HR Officer

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (1.88%), Strs Ohio (0.06%), Hamilton Lane Advisors LLC (0.04%), DNB Asset Management AS (0.02%), Ritholtz Wealth Management (0.01%) and Diversified Trust Co (0.01%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Peter Kolchinsky and Regina M Paglia.
View institutional ownership trends for Dicerna Pharmaceuticals.

Which institutional investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Ritholtz Wealth Management, and Strs Ohio. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, John B Green, and Regina M Paglia.
View insider buying and selling activity for Dicerna Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Hamilton Lane Advisors LLC, DNB Asset Management AS, and Diversified Trust Co.
View insider buying and selling activity for Dicerna Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $25.34.

How big of a company is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals has a market capitalization of $1.90 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 187 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here